Microenvironment and immunology: BPTF depletion enhances T-cell-mediated antitumor immunity

Cancer Research

Volumn 76, Issue 21, 2016, Pages 6183-6192

  Mayes, Kimberly ^a   Alkhatib, Suehyb G ^a   Peterson, Kristen ^a   Alhazmi, Aiman ^a   Song, Carolyn ^a   Chan, Vivian ^a   Blevins, Tana ^b   Roberts, Mark ^a   Dumur, Catherine I ^b   Wang, Xiang Yang ^a   Landry, Joseph W ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN PHD FINGER CONTAINING TRANSCRIPTION FACTOR; CD69 ANTIGEN; GEMCITABINE; HERMES ANTIGEN; ONX 0914; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; FETAL ALZHEIMER ANTIGEN; NERVE PROTEIN; NUCLEOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL INFILTRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; IN VITRO STUDY; METASTASIS; MOUSE; NOD SCID GAMMA MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSMB8 GENE; PSMB9 GENE; REGULATORY SEQUENCE; SPLEEN WEIGHT; T CELL DEPLETION; T LYMPHOCYTE; TAP1 GENE; TAP2 GENE; TUMOR GENE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM; NUCLEOSOME; PHYSIOLOGY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; NERVE TISSUE PROTEINS; NUCLEOSOMES; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 84995550986     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3125     Document Type: Article

References (50)

1. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
2. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37.
3. Woodcock CL, Ghosh RP. Chromatin higher-order structure and dynamics. Cold Spring Harb Perspect Biol 2010;2:a000596.
4. Becker PB, Workman JL. Nucleosome remodeling and epigenetics. Cold Spring Harb Perspect Biol 2013;5:a017905.
5. Landry J, Sharov AA, Piao Y, Sharova LV, Xiao H, Southon E, et al. Essential role of chromatin remodeling protein Bptf in early mouse embryos and embryonic stem cells. PLoS Genet 2008;4:e1000241.
6. Landry JW, Banerjee S, Taylor B, Aplan PD, Singer A, Wu C. Chromatin remodeling complex NURF regulates thymocyte maturation. Genes Dev 2011;25:275-86.
7. Qiu Z, Song C, Malakouti N, Murray D, Hariz A, Zimmerman M, et al. Functional interactions between NURF and Ctcf regulate gene expression. Mol Cell Biol 2015;35:224-37.
8. Mayes K, Qiu Z, Alhazmi A, Landry JW. ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy. Adv Cancer Res 2014;121:183-233.
9. Alkhatib SG, Landry JW. The nucleosome remodeling factor. FEBS Lett 2011;585:3197-207.
10. Barak O, Lazzaro MA, Lane WS, Speicher DW, Picketts DJ, Shiekhattar R. Isolation of human NURF: a regulator of Engrailed gene expression. EMBO J 2003;22:6089-100.
11. Xiao H, Sandaltzopoulos R, Wang HM, Hamiche A, Ranallo R, Lee KM, et al. Dual functions of largest NURF subunit NURF301 in nucleosome sliding and transcription factor interactions. Mol Cell 2001;8:531-43.
12. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011;11:823-36.
13. Durgeau A, El Hage F, Vergnon I, Validire P, de Montpreville V, Besse B, et al. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J Immunol 2011;187:5532-9.
14. Angeles A, Fung G, Luo H. Immune and non-immune functions of the immunoproteasome. Front Biosci 2012;17:1904-16.
15. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
16. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009;9:900-9.
17. Aslakson CJ, Miller FR. Selective events in themetastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
18. Yu XW, Sha C, Guo YL, Xiao R, Xu Y. High-level expression and characterization of a chimeric lipase from Rhizopus oryzae for biodiesel production. Biotechnol Biofuels 2013;6:29.
19. Wang Y, Wang XY, Subjeck JR, Kim HL. Covalent crosslinking of tumor antigens stimulates an antitumor immune response. Vaccine 2010;28: 6613-20.
20. Hassanin H, Serba S, Schmidt J, Marten A. Ex vivo expanded telomerasespecific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma. Clin Exp Immunol 2009;158:125-32.
21. Nagy PL, Cleary ML, Brown PO, Lieb JD. Genomewide demarcation of RNA polymerase II transcription units revealed by physical fractionation of chromatin. Proc Natl Acad Sci U S A 2003;100:6364-9.
22. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI, Kordula T. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem 2011; 286:39893-903.
23. Dumur CI, Sana S, Ladd AC, Ferreira-Gonzalez A, Wilkinson DS, Powers CN, et al. Assessing the impact of tissue devitalization time on genomewide gene expression analysis in ovarian tumor samples. Diagn Mol Pathol 2008;17:200-6.
24. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.
25. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116:2777-90.
26. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002;168:689-95.
27. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells throughmembrane-bound TGFbeta 1. J Immunol 2009;182:240-9.
28. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477-89.
29. Elvin P, Evans CW. Cell adhesion and experimental metastasis: a study using the B16 malignantmelanoma model system. Eur J Cancer Clin Oncol 1984;20:107-14.
30. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
31. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
32. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715-26.
33. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 2001;193:1319-26.
34. Kuo MH, Allis CD. In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. Methods 1999;19:425-33.
35. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 2011;43:264-8.
36. Wright KL, White LC, Kelly A, Beck S, Trowsdale J, Ting JP. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med 1995;181:1459-71.
37. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009;15:781-7.
38. Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, et al. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol 2013;43:2930-42.
39. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 2013;36:477-89.
40. Hemmer B, Pinilla C, Gran B, Vergelli M, Ling N, Conlon P, et al. Contribution of individual amino acids within MHCmolecule or antigenic peptide to TCR ligand potency. J Immunol 2000;164:861-71.
41. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154:567-76.
42. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
43. Hutchinson S, Sims S, O'Hara G, Silk J, Gileadi U, Cerundolo V, et al. A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. PLoS One 2011;6:e14646.
44. Min W, Pober JS, Johnson DR. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. J Immunol 1996;156:3174-83.
45. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 1998;273:16177-83.
46. Hasim A, Abudula M, Aimiduo R, Ma JQ, Jiao Z, Akula G, et al. Posttranscriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One 2012;7:e44952.
47. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400.
48. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
49. Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One 2010;5:e9657.
50. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets ofmyeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.